Literature DB >> 20489133

Monitoring of biochemical status in children with Duarte galactosemia: utility of galactose, galactitol, galactonate, and galactose 1-phosphate.

Can Ficicioglu1, Christie Hussa, Paul R Gallagher, Nina Thomas, Claire Yager.   

Abstract

BACKGROUND: Duarte galactosemia (DG) is frequently detected in newborn-screening programs. DG patients do not manifest the symptoms of classic galactosemia, but whether they require dietary galactose restriction is controversial. We sought to assess the relationships of selected galactose metabolites (plasma galactose, plasma galactitol, erythrocyte (RBC) galactitol, RBC galactonate, and urine galactitol and galactonate) to RBC galactose 1-phosphate (Gal-1-P), dietary galactose intake, and neurodevelopmental/clinical outcomes in DG children.
METHODS: We studied 30 children 1-6 years of age who had DG galactosemia and were on a regular diet. All participants underwent a physical and ophthalmologic examination and a neurodevelopmental assessment. RBC galactitol, RBC galactonate, RBC Gal-1-P, plasma galactose, plasma galactonate, and urine galactitol and galactonate concentrations were measured.
RESULTS: RBC galactitol and galactonate concentrations were about 2 and 6 times higher, respectively, than control values. Plasma galactose and galactitol concentrations were also about twice the control values. The mean values for RBC Gal-1-P and urine galactitol were within the reference interval. We found a relationship between plasma and urine galactitol concentrations but no relationship between RBC galactose metabolites and urine galactitol. There was a significant relationship between galactose intake and RBC galactose metabolites, especially RBC galactitol (P < 0.0005) and RBC galactonate (P < 0.0005). Galactose intake was not related to the urine galactitol, plasma galactose, or plasma galactitol concentration. RBC galactitol, RBC galactonate, plasma galactose, plasma galactitol, and urine galactonate concentrations showed no relationship with clinical or developmental outcomes.
CONCLUSIONS: DG children on a regular diet have RBC Gal-1-P concentrations within the reference interval but increased concentrations of other galactose metabolites, including RBC galactitol and RBC galactonate. These increased concentrations correlate with galactose intake and neither cause any developmental or clinical pathology during early childhood nor oblige a lactose-restricted diet.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20489133     DOI: 10.1373/clinchem.2010.144097

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  6 in total

1.  Phenotype-Genotype Discrepancy Due to a 5.5-kb Deletion in the GALT Gene.

Authors:  Ariadna González-del Angel; José Velázquez-Aragón; Miguel A Alcántara-Ortigoza; Marcela Vela-Amieva; Nancy Hernández-Martínez
Journal:  JIMD Rep       Date:  2011-09-06

2.  Galactosemia screening with low false-positive recall rate: the Swedish experience.

Authors:  Annika Ohlsson; Claes Guthenberg; Ulrika von Döbeln
Journal:  JIMD Rep       Date:  2011-09-06

3.  Developmental Outcomes of School-Age Children with Duarte Galactosemia: A Pilot Study.

Authors:  Mary Ellen Lynch; Nancy L Potter; Claire D Coles; Judith L Fridovich-Keil
Journal:  JIMD Rep       Date:  2015-02-15

4.  Ovarian function in Duarte galactosemia.

Authors:  Jennifer R Badik; Uriel Castañeda; Tyler J Gleason; Jessica B Spencer; Michael P Epstein; Can Ficicioglu; Kristi Fitzgerald; Judith L Fridovich-Keil
Journal:  Fertil Steril       Date:  2011-06-29       Impact factor: 7.329

5.  Laboratory diagnosis of galactosemia: a technical standard and guideline of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Marzia Pasquali; Chunli Yu; Bradford Coffee
Journal:  Genet Med       Date:  2017-10-26       Impact factor: 8.822

6.  Assessment of lactase activity in humans by measurement of galactitol and galactonate in serum and urine after milk intake.

Authors:  Nathalie Vionnet; Linda H Münger; Carola Freiburghaus; Kathryn J Burton; Grégory Pimentel; François P Pralong; René Badertscher; Guy Vergères
Journal:  Am J Clin Nutr       Date:  2019-02-01       Impact factor: 7.045

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.